Realizing Daiichi Sankyo's Purpose and Contributing to Society’s Sustainable Development
Our Purpose, or reason for being, is “to contribute to the enrichment of quality of life of people around the world,” as stated in the corporate mission. This is not limited to the innovative (branded product) drug business. It also applies to all of Daiichi Sankyo's business activities, including its generic pharmaceutical business, vaccines business, and OTC
*1 business.
The "value creation process" generally refers to the cycle whereby a company creates value through its business activities for the needs of society and its stakeholders, and then circulates that value toward the sustainable development of society as a whole. By showing this process in the diagram below, you can more easily understand how our company is creating value and contributing to a sustainable society.
We invest in both financial and non-financial capital in response to various societal demands, such as fulfilling unmet medical needs, providing a stable supply of high-quality pharmaceutical products, improving access to healthcare, and resolving ESG-related
*2 challenges.
In the value creation process, our Daiichi Sankyo group of companies (the Daiichi Sankyo Group) invests the capital required to address various demands of society (for example, to fulfill unmet medical needs and to improve ESG-related issues), creates value that is worth several times what it has invested through its value chains, and returns the value to its stakeholders. It is a cycle where social capital is enriched, and enriched capital allows for further growth of the Daiichi Sankyo Group, leading to an increasingly affluent society.
Through this cycle, the fundamental framework of the Daiichi Sankyo Group's value creation process reflects our commitment to contributing to the enrichment of quality of life of people around the world, which is in fact our Purpose.
Continuously Challenge Drug Discovery by Leveraging Our Strengths in Science and Technology
In addition to injecting financial and human capital into the value creation process, we also invest social and relationship capital into human networks, such as relationships of trust with healthcare professionals and collaborative research with academia. Combining these different types of capital with our strengths in science and technology, our global organization and human resources, and the strong level of recognition that we have in our home market of Japan, we are able to provide the value we create to contribute to a more affluent and sustainable society.
Among these three strengths, science and technology is very important, and in parallel with it our free and open organizational climate allows researchers to appropriately share skills and knowledge and work together in order to enhance the technologies at their disposal. This organizational climate is also what made it possible in the past to create innovative medicines, such as antilipidemic drugs and antibacterial drugs, that were delivered to patients worldwide because researchers had steadily gained confidence about the company’s potential for drug discovery. Although there have been periods in our history when new drugs had not been discovered, we have continued to believe in our own drug discovery capabilities, leading us to the current oncology products and pipeline, including of course our flagship ADCs
*3.
I believe that trusting our strengths and fulfilling our responsibilities at our own workplace translates into fruitful results. In the future, we will continue to leverage our three strengths, thus enhancing our corporate culture in which individuals think and act on their own initiative and contributing to the fulfillment of our Purpose through the continuity of the Daiichi Sankyo Group’s value creation process.
The word Materiality refers to critical issues that are particularly important for companies to continuously create value, and at Daiichi Sankyo we have determined eight categories of Materiality: four related to the business itself and four related to the business foundation.
"Materiality on Business" contributes directly to our Purpose and forms the foundation of our value creation. These four areas of materiality are:
- Continuously Creating Innovative Pharmaceuticals
- Providing a Stable Supply of High-quality Pharmaceutical Products
- Providing High-quality Medical Information
- Improving access to Healthcare (and allowing us to fulfill unmet medical needs, thereby bringing us closer to achieving our Purpose).
At the same time, for the Daiichi Sankyo Group it is also important to establish a foundation for being socially responsible, competitive, and exceptional in our business activities. We define this as “Materiality on Business Foundations,” which contains the following four areas:
- Promoting Compliance Management
- Corporate Governance Aimed at Fulfilling Our Mission
- Promoting Environmental Management
- Promoting the Success and Development of a Diverse Range of Human Resources Who Can Produce Competitive Advantages.
We are working hard on both Materiality categories to continuously create new value for society.
Through our commitment to the value creation purpose, we will continue to contribute to the enrichment of quality of life of people around the world by working globally as “ONE Daiichi Sankyo” and emphasizing the importance of our spirit of "enthusiastic innovation."